{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T22:07:34Z","timestamp":1781734054172,"version":"3.54.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hypertrophic obstructive cardiomyopathy (HOCM) is a hereditary cardiac disease associated with poor prognosis. Data on septal reduction therapy (SRT), including transcoronary ablation of septal hypertrophy (TASH) and surgical myectomy (SM), are limited. We aimed to evaluate temporal trends, patient characteristics, in-hospital outcomes, and the influence of institutional procedural volumes in a nationwide cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used nationwide administrative data from the German Federal Bureau of Statistics to identify HOCM patients undergoing TASH or SM between 2006 and 2019. Primary outcomes were in-hospital mortality and pacemaker implantation. Multivariable logistic regression assessed associations with institutional procedure volume.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 8,514 SRT procedures, 5,293 (62.2%) were TASH and 3,221 (37.8%) SM. Annual volumes increased for both procedures between 2006 and 2019. SM patients were older (67.4 vs. 60.2\u00a0years), more often male, and had a higher comorbidity burden. Of all centers, 49.3% performed\u2009\u2264\u200920 SM per year, and 76.3% performed\u2009\u2264\u200920 TASH per year. Mitral surgery occurred in 36.1% of SM cases. In-hospital mortality was higher for SM than TASH (6.9% vs. 0.8%), while pacemaker implantation was more frequent with TASH (19.3% vs. 13.1%). Risk of in-hospital mortality after SM was higher in low-volume centers than in large centers (adjusted odds ratio 2.64; 95% confidence interval, 1.49\u20134.66).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SM was performed in older, more comorbid patiens and frequently included concomitant valve surgery. Higher in-hospital mortality at low-volume centers may partially reflect surgical complexity or case mix rather than volume alone. Our findings underscore the need for individualized referral strategies to experienced centers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-025-02773-7","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:19:20Z","timestamp":1759994360000},"page":"842-851","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Temporal trends, patient characteristics and hospital volume outcomes after transcoronary ablation of septal hypertrophy and septal myectomy for treatment of obstructive hypertrophic cardiomyopathy"],"prefix":"10.1007","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1221-7015","authenticated-orcid":false,"given":"Peter Moritz","family":"Becher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian J.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Weimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Remmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Schrage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Patten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Detter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Reichenspurner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulus","family":"Kirchhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Blankenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Seiffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"issue":"1","key":"2773_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.amjmed.2003.05.009","volume":"116","author":"Y Zou","year":"2004","unstructured":"Zou Y et al (2004) Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. Am J Med 116(1):14\u201318","journal-title":"Am J Med"},{"issue":"12","key":"2773_CR2","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.amjcard.2004.03.007","volume":"93","author":"BJ Maron","year":"2004","unstructured":"Maron BJ (2004) Prevalence of hypertrophic cardiomyopathy in a population-based sample of American Indians aged 51 to 77 years (the Strong Heart Study). Am J Cardiol 93(12):1510\u20131514","journal-title":"Am J Cardiol"},{"issue":"12","key":"2773_CR3","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","volume":"65","author":"C Semsarian","year":"2015","unstructured":"Semsarian C (2015) New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol 65(12):1249\u20131254","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"2773_CR4","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","volume":"114","author":"MS Maron","year":"2006","unstructured":"Maron MS et al (2006) Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 114(21):2232\u20132239","journal-title":"Circulation"},{"issue":"20","key":"2773_CR5","first-page":"1977","volume":"379","author":"BJ Maron","year":"2018","unstructured":"Maron BJ (2018) Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med 379(20):1977","journal-title":"N Engl J Med"},{"issue":"23","key":"2773_CR6","doi-asserted-by":"publisher","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","volume":"149","author":"SR Ommen","year":"2024","unstructured":"Ommen SR et al (2024) 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines. Circulation 149(23):e1239\u2013e1311","journal-title":"Circulation"},{"issue":"3","key":"2773_CR7","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jacc.2005.02.090","volume":"46","author":"SR Ommen","year":"2005","unstructured":"Ommen SR (2005) Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 46(3):470\u2013476","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"2773_CR8","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1161\/CIRCULATIONAHA.111.076257","volume":"126","author":"P Sorajja","year":"2012","unstructured":"Sorajja P et al (2012) Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 126(20):2374\u20132380","journal-title":"Circulation"},{"issue":"37","key":"2773_CR9","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E et al (2023) 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J 44(37):3503\u20133626","journal-title":"Eur Heart J"},{"key":"2773_CR10","doi-asserted-by":"crossref","unstructured":"Authors\/Task Force members et al (2014) 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35(39):2733\u20132779","DOI":"10.1093\/eurheartj\/ehu284"},{"issue":"10253","key":"2773_CR11","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto I et al (2020) Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 396(10253):759\u2013769","journal-title":"Lancet"},{"key":"2773_CR12","unstructured":"Writing Committee M et al (2021) 2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Thorac Cardiovasc Surg 162(1):e23\u2013e106"},{"issue":"3","key":"2773_CR13","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1001\/jamacardio.2016.0252","volume":"1","author":"LK Kim","year":"2016","unstructured":"Kim LK et al (2016) Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US nationwide inpatient database, 2003\u20132011. JAMA Cardiol 1(3):324\u2013332","journal-title":"JAMA Cardiol"},{"issue":"21","key":"2773_CR14","doi-asserted-by":"publisher","first-page":"e036387","DOI":"10.1161\/JAHA.124.036387","volume":"13","author":"N Patel","year":"2024","unstructured":"Patel N et al (2024) Procedural volume and outcomes after septal reduction therapies in hypertrophic obstructive cardiomyopathy. J Am Heart Assoc 13(21):e036387","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"2773_CR15","doi-asserted-by":"publisher","first-page":"e030194","DOI":"10.1161\/JAHA.123.030194","volume":"12","author":"VY See","year":"2023","unstructured":"See VY, Wang L (2023) Septal reduction therapy for obstructive hypertrophic cardiomyopathy: volume still matters for septal myectomy. J Am Heart Assoc 12(10):e030194","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"2773_CR16","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/eurheartj\/ehp016","volume":"30","author":"M Alam","year":"2009","unstructured":"Alam M, Dokainish H, Lakkis NM (2009) Hypertrophic obstructive cardiomyopathy-alcohol septal ablation vs. myectomy: a meta-analysis. Eur Heart J 30(9):1080\u20131087","journal-title":"Eur Heart J"},{"issue":"20","key":"2773_CR17","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1136\/heartjnl-2022-320852","volume":"108","author":"D Lawin","year":"2022","unstructured":"Lawin D et al (2022) Gender disparities in alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Heart 108(20):1623\u20131628","journal-title":"Heart"},{"issue":"23","key":"2773_CR18","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1136\/heartjnl-2023-322659","volume":"109","author":"D Lawin","year":"2023","unstructured":"Lawin D et al (2023) Alcohol septal ablation in patients aged 75 years or older with hypertrophic obstructive cardiomyopathy. Heart 109(23):1778\u20131784","journal-title":"Heart"},{"key":"2773_CR19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2147\/CIA.S123704","volume":"12","author":"L Cheddadi","year":"2017","unstructured":"Cheddadi L et al (2017) Efficacy and safety of alcohol septal ablation in patients over 65 years old with obstructive hypertrophic cardiomyopathy. Clin Interv Aging 12:467\u2013473","journal-title":"Clin Interv Aging"},{"issue":"1","key":"2773_CR20","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1186\/s12872-024-04194-2","volume":"24","author":"A Elshahat","year":"2024","unstructured":"Elshahat A et al (2024) The efficacy and safety of alcohol septal ablation stratified by alcohol dosage for patients with hypertrophic obstructive cardiomyopathy: a systematic review and meta-analysis. BMC Cardiovasc Disord 24(1):624","journal-title":"BMC Cardiovasc Disord"},{"key":"2773_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae508","author":"KC Koskinas","year":"2024","unstructured":"Koskinas KC (2024) Obesity and cardiovascular disease: an ESC clinical consensus statement. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehae508","journal-title":"Eur Heart J"},{"issue":"6","key":"2773_CR22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.17310","volume":"7","author":"KM Sauro","year":"2024","unstructured":"Sauro KM et al (2024) Enhanced recovery after surgery guidelines and hospital length of stay, readmission, complications, and mortality: a meta-analysis of randomized clinical trials. JAMA Netw Open 7(6):e2417310","journal-title":"JAMA Netw Open"},{"issue":"11","key":"2773_CR23","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.jcin.2017.03.030","volume":"10","author":"M Liebregts","year":"2017","unstructured":"Liebregts M et al (2017) Outcomes of alcohol septal ablation in younger patients with obstructive hypertrophic cardiomyopathy. JACC Cardiovasc Interv 10(11):1134\u20131143","journal-title":"JACC Cardiovasc Interv"},{"issue":"4","key":"2773_CR24","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jacc.2017.02.080","volume":"70","author":"M Liebregts","year":"2017","unstructured":"Liebregts M, Vriesendorp PA, Ten Berg JM (2017) Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a word of endorsement. J Am Coll Cardiol 70(4):481\u2013488","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"2773_CR25","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.028693","volume":"12","author":"AM Altibi","year":"2023","unstructured":"Altibi AM et al (2023) Hospital procedural volume and clinical outcomes following septal reduction therapy in obstructive hypertrophic cardiomyopathy. J Am Heart Assoc 12(10):e028693","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"2773_CR26","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jchf.2015.06.011","volume":"3","author":"M Liebregts","year":"2015","unstructured":"Liebregts M (2015) A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy. JACC Heart Fail 3(11):896\u2013905","journal-title":"JACC Heart Fail"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-025-02773-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-025-02773-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-025-02773-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:55:26Z","timestamp":1776236126000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-025-02773-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2773"],"URL":"https:\/\/doi.org\/10.1007\/s00392-025-02773-7","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"19 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PMB Becher reports personal fees from AstraZeneca, Ingelheim Boehringer and the German Research Foundation. All outside the submitted work. FJB reports grants from Daiichi Sankyo, Novartis, Pfizer, and Sanofi, non-financial support from ASAHI INTECC, and Inari Medical, personal fees from Amgen, Daiichi Sankyo, Inari Medical, Novartis, and Shockwave. All outside of the submitted work. BS received speaker fee from Abbot, Abiomed, AstraZeneca and Inari as well as research funding from Abiomed. All outside the submitted work. MP reports research grants from Takeda\/Shire and personal fees from Alnylam, Amicus, Astra Zeneca, Bristol-Myers Squibb, Cytokinetics, Pfizer, Sanofi\/Genzyme, Takeda\/Shire. PK received research support for basic, translational, and clinical research projects from European Union, British Heart Foundation, Leducq Foundation, Medical Research Council (UK), and German Center for Cardiovascular Research, from several drug and device companies active in atrial fibrillation and has received honoraria from several such companies in the past, but not in the last three years. Dr. Kirchhof is listed as inventor on two issued patents held by University of Hamburg (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). All outside the submitted work. SB reports grants and personal fees from Abbott Diagnostics, Bayer, Siemens, and Thermo Fisher; grants from Singulex; and personal fees from Abbott, AstraZeneca, Amgen, Medtronic, Pfizer, Roche, Siemens Diagnostics, and Novartis, all outside of the submitted work. MS reports personal fees and non-financial support from Abbott Vascular, personal fees from Abiomed, personal fees from AstraZeneca, grants, personal fees and non-financial support from Boston Scientific, personal fees from Bristol-Myers Squibb, personal fees and non-financial support from Edwards Lifesciences, grants and personal fees from Philips, personal fees from Medtronic, personal fees from Amgen, personal fees from Shockwave Medical, personal fees from Daichii Sankyo, personal fees from Pfizer, personal fees from Siemens Healthineers, personal fees from Inari Medical. All outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}